A5067860129- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Hematopoietic Stem Cell Transplantation
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Cancer therapeutics and mechanisms
- Bone health and treatments
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Bone fractures and treatments
- Renal Transplantation Outcomes and Treatments
- Gastrointestinal disorders and treatments
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Chemotherapy-related skin toxicity
- Cancer Genomics and Diagnostics
- Oral health in cancer treatment
- Hematological disorders and diagnostics
- Chemokine receptors and signaling
Royal Adelaide Hospital
2016-2025
Central Adelaide Local Health Network
2022-2024
The University of Sydney
2023
Institute for Computer Science and Control
2020
Budapest University of Technology and Economics
2020
South Australia Pathology
2007-2019
St Vincent's Hospital
2017
Westmead Hospital
2009
Princess Alexandra Hospital
2009
Canberra Hospital
2009
Purpose This phase III international study compared the efficacy and safety of a combination pegylated liposomal doxorubicin (PLD) plus bortezomib with monotherapy in patients relapsed or refractory multiple myeloma. Patients Methods Six hundred forty-six were randomly assigned to receive either intravenous 1.3 mg/m 2 on days 1, 4, 8, 11 an every 21-days cycle, same regimen PLD 30 day 4. Results Median time progression was increased from 6.5 months for 9.3 + (P = .000004; hazard ratio, 1.82...
Thalidomide is effective in the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM). However, role thalidomide post-autologous stem cell transplantation (ASCT) context remains unclear. This study assessed whether addition consolidation following ASCT would improve durability responses achieved overall survival.Between January 2002 March 2005, 269 patients with MM who disease stabilization or better conventional induction chemotherapy received a single high-dose...
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus alone the primary analysis of CASTOR, phase 3 study relapsed and/or refractory multiple myeloma. A post hoc based on treatment history longer follow up is presented. After 19.4 (range: 0-27.7) months median up, daratumumab plus prolonged progression-free survival (median: 16.7 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39;...
Background Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment. It unclear why myelomas peculiarly sensitive to bortezomib, or what causes primary acquired resistance. The ‘unfolded protein response’ is necessary for folding assembly immunoglobulin chains in both normal malignant as well disposal incorrectly folded unpaired via...
Abstract RANKL is a key mediator of osteoclast differentiation, activation, and survival. Preclinical data suggest that aberrant production activation osteoclasts may influence proliferation multiple myeloma (MM) cells in the bone marrow. Reports have also shown inhibiting direct effect on RANK‐expressing therapeutic role treating disease. In mouse models, inhibition led to reduced serum paraprotein levels tumor burden. Based this hypothesis, proof‐of‐concept, single‐arm study investigated...
In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. a randomized trial, we tested whether similar improvements would be observed was bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen. Transplant-ineligible untreated myeloma were receive VCD or plus (VCDD). A total of 121 randomized: 57 in arm 64 VCDD arm. Baseline characteristics balanced between 2 arms. The median progression-free survival...
BACKGROUND Previous results from an interim analysis of open‐label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to monotherapy in patients relapsed/refractory multiple myeloma who had previously received one or more lines therapy. Protocol‐defined final survival data are provided here. METHODS Patients were randomized (1:1) receive either alone (1.3 mg/m 2 intravenously on days 1, 4, 8, and 11 every 21‐day cycle)...
Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus (Vd) alone and exhibited tolerability in relapsed or refractory MM (RRMM). Methods This subgroup analysis evaluated D-Vd Vd CASTOR based on risk, determined using fluorescence situ hybridization and/or karyotype testing performed locally. High-risk had t(4;14), t(14;16), del17p...
Letter to Blood| March 2, 2023 TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype Devendra Hiwase, Hiwase Department of Haematology, Royal Adelaide Hospital, Central Local Health Network, Adelaide, SA, AustraliaPrecision Medicine Theme, South Australian and Medical Research Institute (SAHMRI), AustraliaAdelaide School, University AustraliaCentre for Cancer Biology, Australia SA Pathology, https://orcid.org/0000-0002-6666-3056 Search other works by this...
Plasma cell dyscrasias (PCD) are a spectrum of disorders resulting from the clonal expansion plasma cells, ranging pre-malignant condition monoclonal gammopathy undetermined significance (MGUS) to multiple myeloma (MM). MM generates significant burden disease on community and it is predicted that will increase in both incidence prevalence owing an ageing population longer survival secondary new therapeutic options. Robust comprehensive clinical data currently lacking but required define...
PURPOSE To study the toxicity and efficacy of combined granulocyte colony-stimulating factor (G-CSF) granulocyte-macrophage (GM-CSF) administration for mobilization hematopoietic progenitor cells (HPCs). MATERIALS AND METHODS Cohorts a minimum five patients each were treated subcutaneously as follows: G-CSF 5 micrograms/kg on days 1 to 12 GM-CSF at .5, 1, or 7 (cohorts 2, 3); (cohort 4); 5). Ten-liter aphereses performed (baseline, pre-CSF), 5, 7, 11, 13. Colony assays colony-forming units...
Abstract Purpose: Multiple myeloma is an incurable disease with heterogeneous clinical behavior. Bortezomib has offered some patients relapsed and refractory opportunity for prolonged survival. However, there remains a paucity of data in treated bortezomib that accurately delineates identifies such patients. This information crucial to guide management. Experimental Design: In this study, we aimed identify the most likely respond salvage therapy. We analyzed baseline variables profiled...
Curriculum prerequisite networks have a central role in shaping the course of university programs. The analysis has attracted lot research interest recently since designing an appropriate network is great importance both academically and economically. It determines learning goals program also huge impact on completion time dropping out. In this article, we introduce data-driven probabilistic student flow approach to characterize study distribution graduation based topology rate courses. We...
Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in bone marrow. More than 80% patients with MM display evidence disease (MBD), formation osteolytic lesions throughout axial and appendicular skeleton. MBD significantly increases risk skeletal-related events such as pathologic fracture, spinal cord compression hypercalcaemia. result cells-mediated activation osteoclast activity suppression osteoblast activity. Bisphosphonates (BP),...
Multiple myeloma is an incurable hematologic malignancy characterized by increased bone marrow angiogenesis and extensive lytic disease. We have previously shown that elevated levels of stromal-derived factor-1alpha (SDF-1alpha) in peripheral blood plasma are associated with osteolysis multiple patients. now examined whether SDF-1alpha also correlate angiogenesis.We the contribution cell-derived stimulation vitro using a tube formation assay. collected trephine samples from patients to...